Genflow announced that Tamara Joseph and Dr. Guy-Charles Fanneau de la Horie will join the Board as Independent Non-Executive Directors with immediate effect. Ms. Tamara Joseph: Tamara, a US resident, has extensive experience in both early-stage and commercial biotech companies in the US. Her expertise, within the biotech sector, includes public and private financings, M&A, global expansions and a Nasdaq uplisting.

She has also supported Nasdaq financings in excess of $800 million. Her experience, spanning over 20 years, includes acting as a member of the executive team (as Chief Legal Officer and General Counsel) at multiple US publicly listed companies. Tamara is currently serving as Chief Legal Officer at Nasdaq listed, pharmaceutical firm, Spero Therapeutics Inc., a multi-asset, clinical-stage biopharmaceutical company.

She previously served as Chief Legal Officer at Nasdaq listed, Millendo Therapeutics Inc., to support its transition to a publicly traded company, and as General Counsel at Enzyvant Therapeutics Inc., a rare disease company focused on regenerative medicine which is now a subdivision of Sumitomo Pharma. Previously, Tamara has served as an adviser to the boards of five US publicly traded biotechs, including Cubist Pharmaceuticals Inc. (that was acquired by global healthcare leader, Merck & Co). She currently holds two board and advisory roles with Heluna Health PHFE ("Heluna"), a Los Angeles based,leading fiscal sponsor for US public health programmes; and Boston based therapeuticnon-profit organisation, BINA Farm.

Within Heluna, Tamara is a member of its Executive Committee and Governance Committee. Tamara's appointment reflects Genflow's aim of strengthening its presence in the US, where the longevity sector has gained enormous attention and attracted significant investment capital in excess of $3 billion last year following investments made by high profile,ultra-high-net-worth individuals. Dr. Guy-Charles Fanneau de la Horie: Over the past 20 years, Guy-Charles has built, and led, biotech executive teams where he has acted as Chief Executive Officer.

During his tenures, he has successfully led IPOs and completed multiple fundraisings. Guy-Charles' expertise in the biotech field in both public and private companies encompasses launching and selling new drugs in untapped markets, with successful early access programs. Specifically, Guy-Charles has served as Chief Executive Officer at three biotech companies, including,until very recently,Euronext Growth traded, Pherecydes Pharma, abiotech company that develops treatments against resistant bacterial infections; and Neovacs, a therapeutic vaccine company. Guy-Charles has also held senior positions at Biogen, a Nasdaq listed global biotechnology company.

Guy-Charles managed the IPO and associated successful financing of Neovacsin 2010,and in 2021, led Pherecydes Pharma through an oversubscribed placing. The Company also announced that Dr. Gabrielle Silver, Independent Non-Executive Director, is stepping down from the Board owing to her time commitments and to focus on her other board roles.  In addition,  Professor Andrew Scott, is also stepping down as a Non-Executive Director in order to devote more time to his research and writing, aimed at raising awareness around longevity more broadly amongst the public and policymakers. The Board would like to take this opportunity to thankGabrielle andAndrew for their valuable contribution to the Company over the course of Genflow's listing journey and landmark IPO.